Stability of 5-aminolevulinic acid in aqueous solution

European Journal of Pharmaceutical Sciences

Volumn 7, Issue 2, 1999, Pages 87-91

  Elfsson, B ^a   Wallin, I ^a   Eksborg, S ^a   Rudaeus, K ^a   Ros, A M ^a   Ehrsson, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 Aminolevulinic acid; Acid dissociation constants; Liquid chromatography; Stability

Indexed keywords

AMINOLEVULINIC ACID; EDETIC ACID;

AQUEOUS SOLUTION; ARTICLE; DRUG DEGRADATION; DRUG STABILITY; IN VITRO STUDY; PH; POTENTIOMETRY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TEMPERATURE;

AMINOLEVULINIC ACID; DRUG STABILITY; EDETIC ACID; HYDROGEN-ION CONCENTRATION; SOLUTIONS; TEMPERATURE;

EID: 0032935070     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(98)00009-8     Document Type: Article

References (24)

1. Bech Ø., Berg K., Moan J. The pH dependency of protoporphyrin IX formation in cells incubated with 5-aminolevulinic acid. Cancer Lett. 113:1997;25-29.
2. Butler A.R., George S. The nonenzymatic cyclic dimerisation of 5-aminolevulinic acid. Tetrahedron. 48:1992;7879-7886.
3. Cairnduff F., Stringer M.R., Hudson E.J., Ash D.V., Brown S.B. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br. J. Cancer. 69:1994;605-608.
4. Chang S.C., MacRobert A.J., Bown S.G. Biodistribution of protoporphyrin IX in rat urinary bladder after intravesical instillation of 5-aminolevulinic acid. J. Urol. 155:1996;1744-1748.
5. Daniel, W.W., 1978. Applied nonparametric statistics. Houghton Mifflin Company, Boston.
6. Diddens H., Hümpel B., Hüttmann G., Novo M. Chemische instabilität von 5-aminolaevulinsäure: pH und konzentrationsabhängigkeit. Lasermedizin. 10:1994;106.
7. Edwards S.R., Shanley B.C., Reynoldson J.A. Neuropharmacology of δ-aminolevulinic acid - effect of acute administration in rodents. Neuropharmacology. 23:1984;477-481.
8. Fijan S., Hönigsmann H., Ortel B. Photodynamic therapy of epithelial skin tumours using δ-aminolaevulinic acid and desferrioxamine. Br. J. Dermatol. 133:1995;282-288.
9. Franck B., Stratmann H. Condensation products of the porphyrin precursor 5-aminolevulinic acid. Heterocycles. 15:1981;919-923.
10. Gossner L., Sroka R., Hahn E.G., Ell C. Photodynamic therapy: successful destruction of gastrointestinal cancer after oral administration of aminolevulinic acid. Gastrointest. Endosc. 41:1995;55-58.
11. Heyerdahl H., Wang I., Liu D.L., Berg R., Andersson-Engels S., Peng Q., Moan J., Svanberg S., Svanberg K. Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues. Cancer Lett. 112:1997;225-231.
12. Jaffe E.K., Rajagopalan J.S. Nuclear magnetic resonance studies of 5-aminolevulinate demonstrate multiple forms in aqueous solution. Bioorg. Chem. 18:1990;381-394.
13. Kennedy J.C., Pottier R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J. Photochem. Photobiol. B: Biol. 14:1992;275-292.
14. Kennedy J.C., Pottier R.H., Pross D.C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J. Photochem. Photobiol. B: Biol. 6:1990;143-148.
15. Kriegmair M., Baumgartner R., Knuechel R., Steinbach P., Ehsan A., Lumper W., Hofstädter F., Hofstetter A. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology. 44:1994;836-841.
16. Loh C.S., MacRobert A.J., Bedwell J., Regula J., Krasner N., Bown S.G. Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. Br. J. Cancer. 68:1993;41-51.
17. Martin A., Tope W.D., Grevelink J.M., Starr J.C., Fewkes J.L., Flotte T.J., Deutsch T.F., Anderson R.R. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implication for photodynamic treatment. Arch. Dermatol. Res. 287:1995;665-674.
18. Novo M., Hüttmann G., Diddens H. Chemical instability of 5-aminolevulinic acid used in the fluorescence diagnosis of bladder tumours. J. Photochem. Photobiol. B: Biol. 34:1996;143-148.
19. Peng Q., Warloe T., Berg K., Moan J., Kongshaug M., Giercksky K.E., Nesland J.M. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer. 79:1997;2282-2308.
20. Peng Q., Warloe T., Moan J., Heyerdahl H., Steen H.B., Nesland J.M., Giercksky K.E. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem. Photobiol. 62:1995;906-913.
21. Rhodes L.E., Tsoukas M.M., Anderson R.R., Kollias N. Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. J. Invest. Dermatol. 108:1997;87-91.
22. Steinbach P., Kriegmair M., Baumgartner R., Hofstädter F., Knüchel R. Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite is limited to urothelial cells. Urology. 44:1994;676-681.
23. Svanberg K., Andersson T., Killander D., Wang I., Stenram U., Andersson-Engels S., Berg R., Johansson J., Svanberg S. Photodynamic therapy of nonmelanoma malignant tumours of the skin using topical δ-aminolevulinic acid sensitization and laser irradiation. Br. J. Dermatol. 130:1994;743-751.
24. Szeimies R.M., Sassy T., Landthaler M. Penetration potency of topical applied δ-aminolevulinic acid for photodynamic therapy of basal cell carcinoma. Photochem. Photobiol. 59:1994;73-76.